The cancer therapeutics developer has filed to float on the Nasdaq Global Market, with Taiho Ventures set to achieve an exit.
Werewolf Therapeutics, a US-based oncology therapy developer backed by pharmaceutical firm Taiho, filed for a $100m initial public offering (IPO) on the Nasdaq Global Market yesterday. Founded by life sciences investment firm MPM Capital with an undisclosed amount of seed funding in 2017, Werewolf is developing cancer-focused biotherapeutics which involve using its protein engineering platform…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.